Investigating treatments for lethal prostate cancer linked to DNA damage repair issues
Official title: Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer
Funded at Icahn School of Medicine at Mount Sinai · NIH-11045016 · Data updated 2026-11-12
This study is looking at how changes in certain genes, especially BRCA2, might make prostate cancer harder to treat with hormone therapy, and it aims to find new ways to help patients by testing a combination of targeted radiation and other treatments for those with specific gene issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $722,240 |
| NIH project number | 5R01CA274967-03 |
| Project ID | NIH-11045016 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include men diagnosed with advanced prostate cancer who have alterations in DNA damage repair genes, especially BRCA2.
✕Less likely to help
Patients with early-stage prostate cancer or those without alterations in DDR genes may not benefit from this research.
What this research studies
This research focuses on understanding how alterations in DNA damage repair genes, particularly BRCA2, contribute to resistance against androgen deprivation therapy (ADT) in prostate cancer. By using advanced CRISPR technology, the study aims to explore the molecular mechanisms that lead to treatment resistance and the progression of lethal prostate cancer. The researchers will analyze a wide range of DDR-associated genes to identify potential therapeutic targets and evaluate the effectiveness of combining PSMA-targeted radiotherapy with PARP inhibitors in patients with DDR-deficient prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with lethal prostate cancer, particularly those resistant to current therapies.
How similar studies have gone: Previous research has shown promising results in targeting DNA damage repair pathways in cancer, indicating potential for success with this novel approach.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Chakraborty, Goutam — Icahn School of Medicine at Mount Sinai
- Study coordinator: Chakraborty, Goutam
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.